Insider Trading activities of Glycomimetics Inc (GLYC)

Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Glycomimetics Inc (GLYC) since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Glycomimetics Inc since year 2005. Table 2 shows the detailed insider transactions of Glycomimetics Inc since 2005. The reporting company's ticker symbol is GLYC. The reporting company's CIK number is 1253689.
The total value of stock buying since 2005 is $32,149,975.
The total value of stock sales since 2005 is $1,772,293.
The total value of stock option exercises since 2005 is $149,499.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Glycomimetics Inc (GLYC).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-10 0 $0 25,000 $350,212 0 $0
2018-06 0 $0 19,345 $348,983 5,260 $5,891
2018-05 0 $0 28,617 $509,667 1,491 $492
2017-12 0 $0 2,000 $30,020 0 $0
2017-09 0 $0 2,000 $26,000 0 $0
2017-05 0 $0 4,000 $55,420 8,928 $9,999
2016-12 5,000 $30,050 0 $0 0 $0
2016-10 0 $0 4,000 $28,020 0 $0
2016-07 0 $0 24,000 $169,953 0 $0
2016-06 0 $0 0 $0 605 $677
2016-03 10,397 $49,635 0 $0 0 $0
2016-02 0 $0 0 $0 11,689 $13,091
2015-11 0 $0 1,808 $12,492 0 $0
2015-02 0 $0 0 $0 5,000 $5,600
2014-12 0 $0 27,982 $241,526 0 $0
2014-06 11,000 $70,290 0 $0 100,000 $112,000
2014-04 0 $0 0 $0 1,562 $1,749
2014-01 4,000,000 $32,000,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Glycomimetics Inc insiders (GLYC)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-10-18 Magnani John L. (SVP of Research, CSO) Sale 3,527 14.02 49,448
2018-10-17 Magnani John L. (SVP of Research, CSO) Sale 7,273 14.00 101,822
2018-10-16 Magnani John L. (SVP of Research, CSO) Sale 14,200 14.01 198,942
2018-06-11 Hahn Brian M. (CFO) Sale 19,345 18.04 348,983
2018-06-11 Hahn Brian M. (CFO) Option Ex 5,260 1.12 5,891
2018-05-23 Magnani John L. (SVP of Research, CSO) Option Ex 1,491 .33 492
2018-05-10 Nea Partners 10 L P (10% Owner) Sale 9,539 17.81 169,889
2018-05-10 Barrett M James (Director) Sale 9,539 17.81 169,889
2018-05-10 Barris Peter J (10% Owner) Sale 9,539 17.81 169,889
2017-12-08 Thackray Helen M. (SVP Clinical Development, CMO) Sale 2,000 15.01 30,020
2017-09-18 Thackray Helen M. (SVP Clinical Development, CMO) Sale 2,000 13.00 26,000
2017-05-25 Thackray Helen M. (SVP Clinical Development, CMO) Sale 2,000 15.57 31,140
2017-05-19 Thackray Helen M. (SVP Clinical Development, CMO) Sale 2,000 12.14 24,280
2017-05-10 Magnani John L. (SVP of Research, CSO) Option Ex 8,928 1.12 9,999
2016-12-20 Junius Daniel M (Director) Buy 5,000 6.01 30,050
2016-10-03 Thackray Helen M. (VP Clinical Development, CMO) Sale 4,000 7.00 28,020
2016-07-20 Thackray Helen M. (VP Clinical Development, CMO) Sale 2,000 8.00 16,000
2016-07-06 Thackray Helen M. (VP Clinical Development, CMO) Sale 6,796 6.68 45,397
2016-07-05 Thackray Helen M. (VP Clinical Development, CMO) Sale 10,136 7.01 71,053
2016-07-01 Thackray Helen M. (VP Clinical Development, CMO) Sale 5,068 7.40 37,503
2016-06-29 Baldwin John J. (Director) Option Ex 605 1.12 677
2016-03-04 Goldberg Mark Alan (Director) Buy 10,397 4.77 49,635
2016-02-05 Top Franklin H Jr (Director) Option Ex 11,689 1.12 13,091
2015-11-16 Sandell Scott D (10% Owner) Sale 452 6.91 3,123
2015-11-16 Nea Partners 10 L P (10% Owner) Sale 452 6.91 3,123
2015-11-16 Barrett M James (Director) Sale 452 6.91 3,123
2015-11-16 Barris Peter J (10% Owner) Sale 452 6.91 3,123
2015-02-27 Hahn Brian M. (CFO) Option Ex 5,000 1.12 5,600
2014-12-22 Henos Michael A (Director) Sale 10,659 8.44 89,908
2014-12-19 Henos Michael A (Director) Sale 10,598 8.61 91,280
2014-12-17 Henos Michael A (Director) Sale 5,121 8.97 45,935
2014-12-15 Henos Michael A (Director) Sale 1,604 8.98 14,403
2014-06-18 King Rachel K. (President, CEO) Option Ex 100,000 1.12 112,000
2014-06-13 Henos Michael A (Director) Buy 5,000 6.21 31,050
2014-06-12 Henos Michael A (Director) Buy 6,000 6.54 39,240
2014-04-03 Henos Michael A (Director) Option Ex 1,562 1.12 1,749
2014-01-15 Weller Harry R (10% Owner) Buy 512,500 8.00 4,100,000
2014-01-15 Sandell Scott D (10% Owner) Buy 1,000,000 8.00 8,000,000
2014-01-15 Nea Partners 10 L P (10% Owner) Buy 487,500 8.00 3,900,000
2014-01-15 Barrett M James (Director) Buy 1,000,000 8.00 8,000,000
2014-01-15 Barris Peter J (10% Owner) Buy 1,000,000 8.00 8,000,000

Insider trading activities including stock purchases, stock sales, and option exercises of GLYC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Glycomimetics Inc (symbol GLYC, CIK number 1253689) see the Securities and Exchange Commission (SEC) website.